Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Prediction of Late Rectal Complication Following High-dose-rate Intracavitary Brachytherapy in Cancer of the Uterine Cervix

자궁경부암 환자의 고선량률 강내치료 시행 시 직장합병증의 예측

  • Lee, Jeung-Eun (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung-Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Do-Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn, Yong-Chan (Department of Radiation Oncology, Samsung Medical Center)
  • 이정은 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 허승재 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 박원 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 임도훈 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 안용찬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과)
  • Published : 2003.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Although high-dose-rate intracavitary radiotherapy (HDR ICR) has been used in the treatment of cervical cancer, the potential for increased risk of late complication, most commonly in the rectum, is a major concern. We have previously reported on 136 patients treated with HDR brachytherapy between 1995 and 1999. The purpose of this study is to upgrade the previous data and confirm the correlation between late rectal complication and rectal dose in cervix cancer patients treated with HDR ICR. Materials and Methods: A retrospective analysis was peformed for 222 patients with cevix cancer who were treated for curative intent with external beam radiotherapy (EBRT) and HDR ICR from July 1995 to December 2001. The median dose of EBRT was 50.4 (30.6$\~$56.4) Gy with a daily fraction size 1.8 Gy. A total of six fractions of HDR ICR were given twice weekly with fraction size of 4 (3$\~$5.5) Gy to A point by Iridium-192 source. The rectal dose was calculated at the rectal reference point using the barium contrast criteria. in vivo measurement of the rectal dose was peformed with thermoluminescent dosimeter (TLD) during HDR ICR. The median follow-up period was 39 months, ranging from 6 to 90 months. Results: Twenty-one patients (9.5$\%$) experienced late rectal bleeding, from 3 to 44 months (median, 13 months) after the completion of RT. The calculated rectal doses were not different between the patients with rectal bleeding and those without, but the measured rectal doses were higher in the complicated patients. The differences of the measured ICR rectal fractional dose, ICR total rectal dose, and total rectal biologically equivalent dose (BED) were statistically significant. When the measured ICR total rectal dose was beyond 16 Gy, when the ratio of the measured rectal dose to A point dose was beyond 70$\%$, or when the measured rectal BED was over 110 Gy$_{3}$, a high possibility of late rectal complication was found. Conclusion: Late rectal complication was closely correlated with measured rectal dose by in vivo dosimetry using TLD during HDR ICR. If data from in vivo dosimetry shows any possibility of rectal bleeding, efforts should be made to reduce the rectal dose.

목적: 자궁경부암의 고선량률 근접치료는 근치적 치료에서 중요한 역할을 차지하나 만성합병증 특히 직장합병증의 위험도 증가하게 된다. 이에 저자들은 직장합병증과 직장 방사선선량을 비교하여 합병증과 관련된 인자를 알아보고자 하였다. 대상 및 방법: 1995년 7월부터 2001년 12월까지 자궁경부암으로 진단받고 근치적 방사선치료로 외부방사선치료와 고선량률 강내치료를 모두 받은 환자 222명을 대상으로 하였다. 외부방사선치료의 총방사선량 중앙값은 50.4 Gy(30.6$\~$56.4 Gy)이고 고선량률 강내치료는 이리듐(Ir)-192를 이용하여 point A에 3$\~$5.5 Gy (중앙값 4 Gy), 조사횟수는 5$\~$8회(중앙값 6회)로 주 2회 조사하여 총 15$\~$32.5 Gy (중앙값 24 Gy)를 조사하였다. 환자의 중앙 추적기간은 39개월(6$\~$90개월)이었다 결과: 만성 직장합병증은 21명(9.5$\%$)에서 관찰되었다. 이들은 모두 직장출혈을 보였으며 다른 합병증은 나타나지 않았다. 직장합병증이 발생하기까지의 시간은 방사선치료 종료 후 3$\~$44개월(중앙값 13개월)이었다. 이전의 결과와 마찬가지로 직장합병증을 보인 군의 계산직장선량은 합병증을 보이지 않았던 군과 비슷하고 그 차이가 통계적으로 유의하지 않았다. 그러나 직장합병증을 보인 군의 측정직장선량의 평균값과 BED는 합병증을 보이지 않았던 군에 비해 높았으며 통계적으로 유의한 차이를 보였다. 측정 직장선량이 16 Gy를 넘거나 측정 직장선량과 A point 선량과의 비가 70$\%$를 넘는 경우 또는 측정 직장선량의 BED가 120 Gy$_{3}$을 넘는 경우는 직장 합병증의 가능성이 유의하게 증가하였다. 결론: 자궁경부암에서 고선량률 강내치료시 TLD를 이용한 생체 내 선량측정을 하고 이를 조정함으로써 만성 직장합병증을 예측하고 그 가능성을 줄일 수 있을 것으로 생각된다.

Keywords

References

  1. CrookJM,EscheBA,ChaplainG,etal. Dose-volume analysis and the prevention of radiation sequelae in cervical cancer. Radiother Oncol 1987;8:321-332 https://doi.org/10.1016/S0167-8140(87)80182-2
  2. Deshpande DD, Shrivastav SK, Pradhan AS, e t a l . Dosimetry of intracavitaryapplications in carcinoma of the cervix: rectal dose analysis. Radiother Oncol 1997;42:163-166 https://doi.org/10.1016/S0167-8140(96)01841-5
  3. Ogino I,Kitamura T, Okamoto N, et al. Late rectal complication following high dose rate intracavitary brachytherapy in cancer of the cervix. Int J Radiat Oncol Biol Phys 1995;31:725-734 https://doi.org/10.1016/0360-3016(94)00547-8
  4. PerezCA,FoxS,LockettMA,etal. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysisoftwo different methods. IntJRadiatOncolBiolPhys 1991;21:885-898
  5. PourquierH,DuboisJB,DelardR. Cancer of theuterine cervix: dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment. Int J Radiat Oncol Biol Phys 1982;8:1887-1895 https://doi.org/10.1016/0360-3016(82)90446-1
  6. Van Lancker M, Storme G. Prediction of severe late complications in fractionated, high dose-rate brachytherapy in gynecological applica-tions. Int J Radiat Oncol Biol Phys 1991; 20:1125-1129 https://doi.org/10.1016/0360-3016(91)90214-O
  7. Cunningham DE, Stryker JA, Velkley DE, e t a l . Routine clinical estimation of rectal, rectosigmoidal, and bladder doses from intracavitary brachytherapy inthetreatmentofcarcinomaof the cervix. Int J Radiat Oncol Biol Phys1981;7:653-660 https://doi.org/10.1016/0360-3016(81)90381-3
  8. Montana GS, Fowler WC. Carcinoma of the cervix: analysis of bladder and rectal radiation dose and complications. Int J Radiat Oncol Biol Phys 1989;16:95-100 https://doi.org/10.1016/0360-3016(89)90015-1
  9. StrykerJA,BartholomewM,VelkleyDE,etal. Bladderandrectal complications following radiotherapy for cervix cancer. Gynecol Oncol 1988;29:1-11 https://doi.org/10.1016/0090-8258(88)90140-0
  10. ChoiP,TeoP,FooW,etal. High-dose-rate remote afterloading irradiation of carcinoma of the cervix in Hong Kong: unexpectedly high complication rate. Clin Oncol 1992;4:186-191 https://doi.org/10.1016/S0936-6555(05)81087-8
  11. ClarkBG, Souhami L,RomanTN, et al. Rectalcom plications in patients with carcinoma of the cervix treated with concomitant cisplatin and externalbeamirradiation withhigh dose rate brachytherapy: a dosimetric analysis. Int J Radiat Oncol Biol Phys 1994;28:1243-1250 https://doi.org/10.1016/0360-3016(94)90501-0
  12. Kapp KS, Stuecklschweiger GF, Kapp DS, et al. Dosimetry of intracavitary placements for uterine and cervical carcinoma: results of orthogonal film, TLD,andCT-assisted techniques. Radiother Oncol 1992;24:137-146 https://doi.org/10.1016/0167-8140(92)90372-2
  13. Orton CG,Wolf-RosenblumS. Dose dependence of complication rates in cervix cancer radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:37-44 https://doi.org/10.1016/0360-3016(86)90413-X
  14. Roman TN, Souhami L, Freeman CR, et al. High dose rate afterloading intracavitary therapy in carcinomaofthecervix. Int J Radiat Oncol Biol Phys 1991;20:921-926 https://doi.org/10.1016/0360-3016(91)90186-8
  15. TeshimaT,ChataniM,HataK,etal . High-dose rate intracavitary therapyforcarcinomaofthe uterine cervix:II. Risk factors for rectal complication. Int J Radiat Oncol Biol Phys 1988;14:281-286
  16. Utley JF, Von Essen CF, Horn RA, et al. High-dose- rate afterloading brachytherapy in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1984;10:2259-2263 https://doi.org/10.1016/0360-3016(84)90231-1
  17. Huh SJ, Lim DH, Ahn YC, etal . Comparison between in vivo dosimetry and barium contrast tachnique for prediction of rectal complications in high-dose-rate intracavitary radiotherapy in cervix cancer patients. Strahlenther Onkol 2003;3:191-196
  18. CreasmanWT. Newgynecologic cancer staging.Gynecol Oncol 1995;58:157-158 https://doi.org/10.1006/gyno.1995.1203
  19. Hall EJ. Repair ofRadiationDamageandtheDose-RateEffect. In:Radiobiologyfortheradiologist.4thed.Philadelphia, PA: J. B. Lippincott Co. 2000:67-90
  20. ChassagneD,SismondiP,Horiot JC,etal. A glossaryforreporting complications of treatment in gynecological cancers. Radiother Oncol 1993;26:195-202 https://doi.org/10.1016/0167-8140(93)90260-F
  21. WachterS, Gerstner N, GoldnerG, et al. Endoscopic scoring of late rectalmucosaldamageafterconformalradiotherapyfor prostatic carcinoma. Radiother Oncol 2000; 54:11-19 https://doi.org/10.1016/S0167-8140(99)00173-5
  22. Ito H, Kutuki S, Nishiguchi I, et al. Radiotherapy for cervical cancer with high-dose rate brachytherapy correlation between tumor size, dose and failure. Radiother Oncol 1994;31:240-247 https://doi.org/10.1016/0167-8140(94)90429-4
  23. KappKS,StuecklschweigerGF,KappDS,etal. Carcinoma of the cervix:analysisofcomplicationsafterprimaryexternalbeam radiation and Ir-192 HDR brachytherapy. Radiother Oncol 1997;42:143-153 https://doi.org/10.1016/S0167-8140(96)01881-6
  24. UnoT,ItamiJ,ArugaM,etal. High dose rate brachytherapy for carcinoma of the cervix: risk factors for late rectal complications. Int J Radiat Oncol Biol Phys 1998;40:615-621 https://doi.org/10.1016/S0360-3016(97)00849-3
  25. Dose,Volume. Specification for Reporting Intracavitary Therapy inGynecology.ICRUReport38. International Commission o n Radiation UnitsandMeasurements, Bethesda. 1985